| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5290 | Ucb-6786 | Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins |
|
| DCC5291 | Ucb-6876 | Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins |
|
| DCC5292 | Ucb-fcrn-303 | Novel allosteric modulator of neonatal Fc receptor (FcRn), binding to the extracellular domain of FcRn |
|
| DCC5293 | uc-ddc-918013 | Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3 |
|
| DCC5294 | uc-ddc-931126 | Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3 |
|
| DCC5295 | uc-ddc-966791 | Competitive dual inhibitor of the hydrolysis FS-3 and the phosphodiesterase substrate p-nitrophenyl thymidine 5'-monophosphate |
|
| DCC5297 | Uck2-in-135546734 | Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|
| DCC5298 | Uck2-in-135546812 | Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|
| DCC5299 | Uck2-in-20874830 | Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors |
|
| DCC5300 | ucl-1972 | Histamine H3 Receptor Antagonist in Treatments of Cognition Disorders |
|
| DCC5301 | Ucl-2190 Hydrogen Maleate | The first potent nonimidazole H3 receptor antagonist (pKi=8.40) |
|
| DCC5302 | Ucm-05194 | Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), Showing Efficacy in Neuropathic Pain Amelioration |
|
| DCC5303 | Ucm-1336 | Novel potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor, improving survival in Ras-driven acute myeloid leukemia |
|
| DCC5304 | Ucm710 | Dual inhibitor of fatty acid amide hydrolase (FAAH) and α/β hydrolase domain 6 (ABHD6) |
|
| DCC5305 | Ucn-02 | Stereoisomer of UCN-01, inhibiting protein kinase C with a slightly reduced potency than UCN-01 |
|
| DCC5306 | Ucp1172 | Novel dual inhibitor of dihydrofolate reductase (DHFR) and its functional analog, Rv2671 |
|
| DCC5307 | Ucph-102f | Fluorescent excitatory amino acid transporter subtype 1 (EAAT1) selective inhibitor |
|
| DCC5308 | Ue2316 | Potent and selective 11ß-HSD1 inhibitor, improving memory, including after intracerebroventricular drug administration to the central nervous system alone |
|
| DCC5309 | Ufp512 | Novel selective delta-opioid receptor agonist |
|
| DCC5310 | Ufr2709 | Novel Nicotinic Acetylcholine Receptor Antagonist, Inhibiting Nicotine Reward and Decreases Anxiety and Decreasing Ethanol Intake in Alcohol-Preferring Rats |
|
| DCC5311 | Ugm-in-1 | Novel inhibitor of UGM, impeding C. glutamicum growth |
|
| DCC5312 | Ugm-in-2 | Novel inhibitor of UGM, impeding C. glutamicum growth |
|
| DCC5313 | Uic-94003 | Novel potent human immunodeficiency virus type 1 (HIV-1) protease inhibito |
|
| DCC5314 | Uk-447841 | Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD) |
|
| DCC5315 | Uk-505749 | Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD) |
|
| DCC5316 | Ukcp-110 | Potent VMAT2 inhibitor |
|
| DCC5317 | Ul-766 | Novel chemically stable fluorescent marker of the ureter |
|
| DCC5318 | Um1024 | Novel Vaccine Adjuvant for Mycobacterium tuberculosis |
|
| DCC5319 | Umb103 | Novel potent and selective dual PLK1 and BRD4 inhibitor, inducing apoptosis in pediatric tumor cell lines, leading to significant tumor regression |
|
| DCC5320 | Umb298 | Novel, Potent, and Selective CBP/P300 Inhibitor |
|
